VC005 tablets: VC005 groups repeat administration for 48 weeks
VC005 Tablets Placebo: VC005 placebo groups repeat administration for 48 weeks
Study summary
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
* The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
* The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis
Exclusion Criteria:
* Those who may be allergic to VC005, similar drugs or their excipients.
* Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.
* Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.
Primary outcome measure(s)
Percentage of patients achieving an Assessment of disease activity (signs and symptoms) in ankylosing spondylitis 20% improvement (ASAS20) in response at week 12 of treatment. — week 12
Trial sites (1)
Facility
City
Region
Status
Peking University People's Hospital
Beijing
Beijing Municipality
Recruiting
More Jiangsu vcare pharmaceutical technology co., LTD trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.